Getting your player ready...
Johnson & Johnson on Friday terminated a partnership to develop a highly touted drug for MRSA and other dangerous skin infections after European regulators rejected it over concerns that testing data aren’t reliable. Switzerland’s Basilea Pharmaceutica Ltd. discovered the compound, called ceftobiprole.
